Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) EBITDA (2016 - 2025)

Historic EBITDA for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to $94000.0.

  • International Stem Cell's EBITDA rose 20444.44% to $94000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $97000.0, marking a year-over-year increase of 11786.37%. This contributed to the annual value of -$68000.0 for FY2024, which is 8974.36% up from last year.
  • As of Q3 2025, International Stem Cell's EBITDA stood at $94000.0, which was up 20444.44% from $167000.0 recorded in Q2 2025.
  • In the past 5 years, International Stem Cell's EBITDA registered a high of $167000.0 during Q2 2025, and its lowest value of -$623000.0 during Q3 2021.
  • Moreover, its 5-year median value for EBITDA was -$97000.0 (2023), whereas its average is -$146684.2.
  • As far as peak fluctuations go, International Stem Cell's EBITDA crashed by 900000.0% in 2024, and later surged by 20444.44% in 2025.
  • International Stem Cell's EBITDA (Quarter) stood at -$323000.0 in 2021, then skyrocketed by 118.89% to $61000.0 in 2022, then plummeted by 795.08% to -$424000.0 in 2023, then surged by 112.03% to $51000.0 in 2024, then surged by 84.31% to $94000.0 in 2025.
  • Its EBITDA was $94000.0 in Q3 2025, compared to $167000.0 in Q2 2025 and -$215000.0 in Q1 2025.